Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
18 08 2023
Historique:
received: 01 11 2022
accepted: 21 07 2023
medline: 21 8 2023
pubmed: 19 8 2023
entrez: 18 8 2023
Statut: epublish

Résumé

Lenalidomide, an immunomodulatory drug (IMiD), is commonly used as a first-line therapy in many haematological cancers, such as multiple myeloma (MM) and 5q myelodysplastic syndromes (5q MDS), and it functions as a molecular glue for the protein degradation of neosubstrates by CRL4

Identifiants

pubmed: 37596276
doi: 10.1038/s41467-023-40385-9
pii: 10.1038/s41467-023-40385-9
pmc: PMC10439208
doi:

Substances chimiques

Lenalidomide F0P408N6V4
Immunomodulating Agents 0
Proteolysis Targeting Chimera 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4683

Informations de copyright

© 2023. Springer Nature Limited.

Références

Cell. 2020 Dec 10;183(6):1714-1731.e10
pubmed: 33275901
Mol Cell. 2020 Mar 5;77(5):1092-1106.e9
pubmed: 31973889
Blood. 2015 Aug 6;126(6):779-89
pubmed: 26002965
Nat Commun. 2022 Jan 10;13(1):183
pubmed: 35013300
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14652-7
pubmed: 12409616
Science. 2014 Jan 17;343(6168):301-5
pubmed: 24292625
Elife. 2018 Aug 01;7:
pubmed: 30067223
N Engl J Med. 2006 Oct 5;355(14):1456-65
pubmed: 17021321
Nat Chem Biol. 2019 Nov;15(11):1077-1084
pubmed: 31591562
Cell Chem Biol. 2023 Mar 16;30(3):235-247.e12
pubmed: 36863346
Nat Cell Biol. 2020 May;22(5):526-533
pubmed: 32251398
Nature. 2014 Aug 7;512(7512):49-53
pubmed: 25043012
Nat Rev Drug Discov. 2022 Mar;21(3):181-200
pubmed: 35042991
Cancer Discov. 2013 Mar;3(3):308-23
pubmed: 23430699
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Bioorg Med Chem Lett. 2008 Nov 15;18(22):5904-8
pubmed: 18752944
Toxicol Appl Pharmacol. 1965 Mar;7:268-86
pubmed: 14298018
Nat Rev Drug Discov. 2021 Oct;20(10):789-797
pubmed: 34285415
Nat Rev Drug Discov. 2017 Feb;16(2):101-114
pubmed: 27885283
Explor Target Antitumor Ther. 2020;1(5):273-312
pubmed: 36046485
Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1355-63
pubmed: 15272157
Nat Rev Cancer. 2021 Oct;21(10):638-654
pubmed: 34131295
Nat Chem Biol. 2020 Nov;16(11):1208-1217
pubmed: 32958952
J Med Chem. 2020 Oct 22;63(20):11615-11638
pubmed: 33026811
Br J Exp Pathol. 1967 Feb;48(1):107-17
pubmed: 6019648
Blood. 2019 Feb 28;133(9):952-961
pubmed: 30545835
Nat Rev Cancer. 2004 Apr;4(4):314-22
pubmed: 15057291
J Am Chem Soc. 2021 Apr 7;143(13):5141-5149
pubmed: 33783207
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Nature. 2016 Jun 22;535(7611):252-7
pubmed: 27338790
Blood. 2021 Feb 4;137(5):661-677
pubmed: 33197925
Signal Transduct Target Ther. 2019 Dec 24;4:64
pubmed: 31885879
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8554-9
pubmed: 11438690
J Am Chem Soc. 2012 Mar 14;134(10):4465-8
pubmed: 22369643
Nat Chem Biol. 2015 Aug;11(8):611-7
pubmed: 26075522
Arch Toxicol. 1988 Jan;61(3):180-91
pubmed: 3355363
Blood Cancer Discov. 2021 May;2(3):250-265
pubmed: 34027417
Nature. 2015 Jul 9;523(7559):183-188
pubmed: 26131937
EMBO J. 2021 Feb 15;40(4):e105375
pubmed: 33470442
Trends Pharmacol Sci. 2012 Mar;33(3):146-53
pubmed: 22277300
J Am Chem Soc. 2010 Apr 28;132(16):5820-6
pubmed: 20369832
Cytokines Cell Mol Ther. 2000 Jun;6(2):61-70
pubmed: 11108571
Nat Commun. 2020 Sep 14;11(1):4578
pubmed: 32929090
Nature. 2016 Apr 7;532(7597):127-30
pubmed: 26909574
Cell Rep. 2021 Apr 27;35(4):109032
pubmed: 33910018
FEBS Lett. 2008 Jan 23;582(2):221-8
pubmed: 18082144
J Med Chem. 2020 Jul 9;63(13):6648-6676
pubmed: 32130004
DNA Res. 2008 Jun 30;15(3):137-49
pubmed: 18316326
Molecules. 2022 Mar 18;27(6):
pubmed: 35335338
Nat Chem Biol. 2021 Jun;17(6):711-717
pubmed: 34035522
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12703-8
pubmed: 23858438
PLoS One. 2016 Jun 06;11(6):e0156716
pubmed: 27271343
J Med Chem. 2018 Jan 25;61(2):535-542
pubmed: 28425720
Science. 2014 Jan 17;343(6168):305-9
pubmed: 24292623
Nat Struct Mol Biol. 2014 Sep;21(9):803-9
pubmed: 25108355
Nat Chem Biol. 2018 Oct;14(10):981-987
pubmed: 30190590
Elife. 2019 Mar 25;8:
pubmed: 30907729
Elife. 2020 May 11;9:
pubmed: 32391793
Science. 2015 Jun 19;348(6241):1376-81
pubmed: 25999370
Science. 2010 Mar 12;327(5971):1345-50
pubmed: 20223979
Science. 2018 Nov 2;362(6414):
pubmed: 30385546
Nat Commun. 2017 May 22;8:15398
pubmed: 28530236
Molecules. 2022 Oct 02;27(19):
pubmed: 36235052
Nat Chem Biol. 2019 Jul;15(7):737-746
pubmed: 31209349

Auteurs

Satoshi Yamanaka (S)

Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, 790-8577, Japan.
Division of Proteo-Interactome, Proteo-Science Center, Ehime University, Matsuyama, 790-8577, Japan.

Hirotake Furihata (H)

Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, 790-8577, Japan.
Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.

Yuta Yanagihara (Y)

Division of Integrative Pathophysiology, Proteo-Science Center, Ehime University, Toon, 791-0295, Japan.

Akihito Taya (A)

Department of Life Science and Applied Chemistry, Nagoya Institute of Technology, Nagoya, 466-8555, Japan.

Takato Nagasaka (T)

Department of Life Science and Applied Chemistry, Nagoya Institute of Technology, Nagoya, 466-8555, Japan.

Mai Usui (M)

Department of Life Science and Applied Chemistry, Nagoya Institute of Technology, Nagoya, 466-8555, Japan.

Koya Nagaoka (K)

Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, 790-8577, Japan.

Yuki Shoya (Y)

Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, 790-8577, Japan.

Kohei Nishino (K)

Division of Cell Signaling, Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima, 770-8503, Japan.

Shuhei Yoshida (S)

Division of Integrative Pathophysiology, Proteo-Science Center, Ehime University, Toon, 791-0295, Japan.

Hidetaka Kosako (H)

Division of Cell Signaling, Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima, 770-8503, Japan.

Masaru Tanokura (M)

Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.

Takuya Miyakawa (T)

Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.
Graduate School of Biostudies, Kyoto University, Kyoto, 606-8502, Japan.

Yuuki Imai (Y)

Division of Integrative Pathophysiology, Proteo-Science Center, Ehime University, Toon, 791-0295, Japan.

Norio Shibata (N)

Department of Life Science and Applied Chemistry, Nagoya Institute of Technology, Nagoya, 466-8555, Japan.

Tatsuya Sawasaki (T)

Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, 790-8577, Japan. sawasaki@ehime-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH